Nanomedicine: Science, Business, and Impact

ISBN-13: 9789814613767 / Angielski / Twarda / 2015 / 428 str.

Michael Hehenberger

Opis

By covering the science, business, and societal impact of nanomedicine, this book makes a strong case for funding of basic research, for effective translation of scientific breakthroughs into clinical care of patients, and for close collaboration among all stakeholders in the healthcare ecosystem. It covers the underlying science and technology of nanomedicine in detail to help understand the great promise of nanomedicine across all disease areas. Although rich and deep in content, the book attempts to introduce the topic of nanomedicine to a wide audience. Scientific jargon is avoided and advanced terms and concepts are explained from the ground up, whenever first introduced. The book defines nanomedicine in a broad sense, including diagnostic devices such as DNA sequencing and molecular imaging, and new therapeutic options based on targeted drug delivery, regenerative medicine, immunotherapeutics, the creation of implanted devices such as continuous glucose monitors and deep brain stimulators, and even the 3D printing of new human organs. It also covers the returns of investment in global scientific projects, such as the Human Genome Project, and the historic and emerging importance of philanthropic foundations.

Spis treści

Dedication. Purpose. Table of Contents. Introduction. What is Nanomedicine?. What is Translational Medicine?. What is Innovation?. What is Intellectual Property?. From IP to IPO. What is Impact?. From Atoms to Proteins. Atoms and Molecules. Atoms of Life. Molecules of Life. Proteins. Genetics and DNA Sequencing. DNA and the Genetic Code. From DNA to Proteins and Cells. History of Genetics. Molecular Basis of Genetics. DNA Sequencing and the Human Genome Project. Sequencing Technologies. Chemical Sequencing. Sanger Sequencing, NGS and the $1,000 Genome Challenge. Second Generation DNA Sequencing. Third Generation DNA Sequencing. Fourth Generation DNA Sequencing. Sequencing Data Analysis. Bioethics. Business Aspects of Sequencing Technology and the Human Genome Project. Post Human Genome Project: "Omics". Bio-Pharmaceutical R&D. Stages of Bio-Pharmaceutical Drug Discovery and Clinical Development. Stage 1: Drug Discovery. Stage 2: Pre-Clinical Research. Stages 3–4: Clinical Trials and FDA Review. The Emerging Importance of "Biologics". Biomarkers and Stratified/Personalized Medicine. The Past and Future of Bio-Pharmaceutical R&D. Semiconductors: Progress through Collaboration. Life Sciences Industry: Exclusive IP Deals and Limited Collaboration. IMI and AMP. Nanomedicine. Computers in Nanomedicine. Biocompatible Nanoparticles and Targeted Drug Delivery. Dendrimers. Liposomes. Targeted Drug Delivery. The Business of Nanotherapeutics. Biomedical and Molecular Imaging. Nanodiagnostics. Regenerative Medicine: Stem Cells, Gene Therapy, Immunotherapy. Impact of Nanomedicine. The Gut Microbiome. Central Nervous System: Brain and Spinal Cord. Cancer and Immunology. Cardiovascular Disease. Diabetes. Infectious Disease. Tissue and Organ Transplantation. The Healthcare Ecosystem AND BIOMEDICAL RESEARCH FUNDING. It’s all about the Patient/Consumer. The Future of Funding for Basic Biomedical and Translational Research. Public Health and Global Health Economics. Global View of Healthcare Costs, Infant Mortality and Life Expectancy. US Health Statistics. Conclusions. Acknowledgments. References.

O autorze

Dr. Michael Hehenberger is founder of HM NanoMed LLC, Connecticut, USA. He retired after a long career with IBM at the end of 2013. He earned a Dipl. Ing. in physics from the Technical University of Vienna, Austria, and obtained his Ph.D. and Dr. Sc. degrees in quantum chemistry from Uppsala University, Sweden, in 1975–79. He also spent two years at the University of Florida, Gainesville, USA, as visiting associate professor. In 1985, he joined IBM in Stockholm, Sweden, to initiate academic partnerships in computational biology, structural engineering, computer networks, and supercomputing. Throughout his IBM career that took him to European Headquarters in Paris, California (Almaden Research, San Jose), and New York, he has led collaborations with academic and global industrial life sciences organizations. The partnerships were based on the joint desire to extend the frontiers of computational chemistry and biology, information-based medicine, biopharmaceutical research, and nanomedicine. His efforts have been documented in over 40 publications and book chapters.